Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on June 12, 2017. The filing reports a material event under Item 8.01 (Other Events). Note: While the request metadata references "Cardiff Oncology, Inc.", the filing text explicitly identifies the registrant as Trovagene, Inc.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses solely on a corporate event rather than periodic financial results.
Material Changes and Events
- Strategic Agreement: On June 12, 2017, Trovagene, Inc. entered into an agreement with AstraZeneca.
- Scope of Agreement: The agreement involves Trovagene providing its Trovera® urine ctDNA biomarker test and related services to AstraZeneca.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the disclosure of the new agreement. The full details of the agreement are referenced in the attached press release (Exhibit 99.1), which is not included in the provided text.
Investor Verification Checklist
- Verify the specific terms, duration, and financial value of the agreement with AstraZeneca by reviewing the attached press release (Exhibit 99.1).
- Confirm the commercial status and regulatory approval of the Trovera® urine ctDNA biomarker test.
- Assess the potential impact of this partnership on Trovagene's future revenue streams and cash burn rate.